IONS · NASDAQ · STOCK
Ionis Pharmaceuticals, Inc.
$55.38
52W $40.37 – $86.74
43/100
$9.21B
-16.0
0.40
Is IONS Bullish or Bearish?
Mixed.
Innellis AI committee rates Ionis Pharmaceuticals, Inc. (IONS) Reduce with a composite score of 43/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Watch
- Requires a committee score of 45.0 — +1.60 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Sell
- Requires the score to fall below 25.0 — -18.40 from today. The band boundary is 30.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
- Revenue declining -7.5% YoY -- this is not a growth story right now — Growth
- Price structure making lower highs and lower lows — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
43/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 100%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 26.2x prices in significant intangible value
Growth Analyst
bearish
15
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -7.5% YoY -- this is not a growth story right now
Technical Analyst
neutral
46
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 4.77) amplifies downside in a stress scenario
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
46.6
Neutral
MACD Histogram
0.970
Bullish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Mixed
Support
$40.14
Resistance
$79.01
Bollinger %B
0.63
Inside Bands
Price vs Moving Averages
EMA 9
$55.37
Above
EMA 21
$57.51
Below
EMA 50
$63.55
Below
EMA 200
$68.00
Below
Fundamental Analysis
Valuation
67
Profitability
25
Financial Health
50
Cash Flow
15
Valuation
P/E Ratio
-16.0×
P/B Ratio
20.85×
PEG Ratio
0.19
Dividend Yield
0.00%
52W High
$86.74
52W Low
$40.37
Quality & Growth
ROE
-7790.0%
ROA
-1081.2%
Gross Margin
9816.2%
Operating Margin
-6808.5%
Revenue Growth YoY
—
Debt / Equity
5.50
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -16.0 (inexpensive relative to a 15-40x range); Price-to-book of 20.8x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -77.9%; Return on assets of -10.8%; Net margin of -64.6%; Gross margin of 98.2%; Current ratio of 7.88 (healthy short-term liquidity); Debt-to-equity of 5.50; Free cash flow per share is negative (-3.38); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full IONS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →